Beam Therapeutics’ Base-Edited CAR-T Placed On Hold
Latest Off-The-Shelf Therapy To Be Delayed
Executive Summary
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.